In 1981, the National Commission, in describing the principles of equitable selection of subjects, stated that women could take part in all research studies. This decision coincided with a publication by Kinney et al. showing that young women served as subjects in premarketing drug trials less frequently than young men. The authors discussed the moral, legal, and medical implications of women’s underrepresentation and the increased risks to female patients because of the denial of medication. Furthermore, safety risks increased when women received certain new drugs only in the postmarketing phase.

It was not until 1991 that 16 federal departments and agencies adopted a single, general set of regulatory provisions governing protections for human subjects. The Common Rule specified how research involving humans was to be conducted and reviewed, including the rules for obtaining informed con-sent. The Common Rule was developed in response to recommendations made by the President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research back in 1981, calling for the adoption by all federal agencies of the U.S. Department of Health and Human Services (DHHS) regulations then in effect to protect human research subjects. The DHHS specified additional protections, as part of the Common Rule, for research on certain populations: pregnant women, fetuses, and patients involved with in vitro fertilization research, prisoners, and children. canadian antibiotics

Although the NIH supposedly addressed the systematic exclusion of women from clinical research in 1986 by adopting a policy requiring their inclusion, a GAO report in 1990 revealed that women were still being excluded from many clinical studies. This led to a public outcry and political pressure that helped secure the establishment of NIH guidelines to include women and minority groups in clinical trials as part of the NIH Revitalization Act of 1993 (Public Law 103-43).

First, the Office of Research on Women’s Health, dedicated to the improvement of women’s health in America, was established in 1990 as part of the NIH. In 1994, the FDA created the Office of Women’s Health (OWH), which established a new chapter in the agency’s commitment to women’s health issues. The Office was concerned with federal policies and public laws regarding the inclusion of women and minorities in clinical research and promoted research directed toward women. The goals were to strengthen, develop, and increase research into diseases, disorders, risk factors, and conditions that were unique to, more prevalent among, or more serious in women.

The 1993 NIH Revitalization Act guidelines demanded the inclusion of women and members of minority groups in all NIH-supported biomedical and behavioral research projects involving human subjects. In investigations of new drugs or therapies, women were included in only approximately 50% of the studies. The Act allowed the restriction on women of childbearing age to be lifted to allow them in early-phase clinical trials. Unless a clear and compelling rationale and justification established that inclusion was inappropriate because of the subject’s health or the purposes of the research, women and minorities had to be included in the studies.
antibiotics online pharmacy

To ensure the inclusion of women in clinical research, new FDA guidelines in 1993 eliminated the earlier policy that had virtually banned women with childbearing potential from entry into the early phases of clinical trials. The guidelines also called for an analysis, by gender, of the safety and effectiveness of drugs and biologicals and identified broad areas of interest in relation to sex-specific factors in responses to drugs. The gender guidelines focused on data needed for drug approval and marketing, with only limited reference to the details of drug development or when and how to study both sexes. Although the guidelines did not require the early participation of women, they indicated that their participation would be of value.

The need to include both women and men in clinical studies was substantiated by analyses of unpublished data from 26 bioequivalence trials submitted to the FDA that showed significant gender differences in approximately 28% of the data sets. Where data variability (areas under the plasma concentration-time curve [AUC] and maximum concentration [Cmax]) differed between the sexes, it was suggested that higher variability in women (within the subgroup) might be more common and that a sex-based subject-by-formulation interaction could occur, although perhaps with low frequency.

Sex-related differences in pharmacokinetics were apparent in the many drugs studied. Dosage adjustment according to body weight may be necessary for drugs that exhibit a steep dose-response curve. Although this study was exploratory, the results supported the FDA’s recommendation in 1993 that women not be excluded from bioequivalence studies.

Following publication of the new gender guidelines in the 1990s, subsequent statistical evaluation of all NIH phase III (extramural) clinical trial studies showed that women repre­sented 67.2% of the enrolled subjects in 1998 and 74.8% of the enrollees in 1997. Earlier phase III NIH (intramural) studies had included fewer women.
pharmacy united kingdom

2000s

Supplementary federal legislation was proposed in October 2001 for the additional protection of human research subjects. The NIH adopted the definition of “clinical” research as patient-oriented (i.e., it was conducted with human subjects for which an investigator [or colleague] directly interacted with them). Patient-oriented research included mechanisms of human disease, therapeutic interventions, clinical trials, development of new technologies, epidemiological and behavioral studies, and outcomes research.

Language governing NIH-defined phase III clinical trials was clarified to be consistent with the mandate for the inclusion of women and minorities as subjects in clinical research (Public Law 103-43), the new Public Health Service 398 Form, and the Office of Management and Budget (OMB) Directive 15.